Effect of dexmedetomidine on tourniquet-induced skeletal muscle injury
Rev. Assoc. Med. Bras. (1992, Impr.)
;
69(2): 228-232, Feb. 2023. graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1422623
ABSTRACT
SUMMARY OBJECTIVE:
The aim of this study was to investigate whether dexmedetomidine could reduce tourniquet-induced skeletal muscle injury.METHODS:
C57BL6 male mice were randomly assigned to sham, ischemia/reperfusion, and dexmedetomidine groups. Mice in the ischemia/reperfusion and dexmedetomidine groups received normal saline solution and dexmedetomidine intraperitoneally, respectively. The sham group underwent the same procedure as the ischemia/reperfusion group, with the exception of tourniquet application. Subsequently, the ultrastructure of the gastrocnemius muscle was observed, and its contractile force was examined. In addition, Toll-like receptor 4 and nuclear factor-κB expression within muscles was detected by Western blot.RESULTS:
Dexmedetomidine alleviated myocyte damage and increased the contractility of skeletal muscles. Moreover, dexmedetomidine significantly inhibited the expression of Toll-like receptor 4/nuclear factor-κB in the gastrocnemius muscle.CONCLUSION:
Taken together, these results demonstrate that dexmedetomidine administration attenuated tourniquet-induced structural and functional impairment of the skeletal muscle, partly through inactivation of the Toll-like receptor 4/nuclear factor-κB pathway.
Full text:
Available
Index:
LILACS (Americas)
Language:
English
Journal:
Rev. Assoc. Med. Bras. (1992, Impr.)
Journal subject:
EducaÆo em Sa£de
/
GestÆo do Conhecimento para a Pesquisa em Sa£de
/
Medicine
Year:
2023
Type:
Article
Affiliation country:
China
Institution/Affiliation country:
Tianjin Hospital/CN
Similar
MEDLINE
...
LILACS
LIS